EDIT
Price
$2.58
Change
-$0.17 (-6.18%)
Updated
Sep 25 closing price
Capitalization
396.24M
43 days until earnings call
Intraday BUY SELL Signals
GYRE
Price
$7.35
Change
+$0.02 (+0.27%)
Updated
Sep 25 closing price
Capitalization
779.35M
52 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EDIT vs GYRE

EDIT vs GYRE Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
EDIT vs. GYRE commentary
Sep 28, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and GYRE is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
EDIT vs GYRE: Fundamental Ratings
EDIT
GYRE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
99
Overvalued
PROFIT vs RISK RATING
1..100
10091
SMR RATING
1..100
9995
PRICE GROWTH RATING
1..100
6242
P/E GROWTH RATING
1..100
1006
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (35) in the Biotechnology industry is somewhat better than the same rating for GYRE (99) in the null industry. This means that EDIT’s stock grew somewhat faster than GYRE’s over the last 12 months.

GYRE's Profit vs Risk Rating (91) in the null industry is in the same range as EDIT (100) in the Biotechnology industry. This means that GYRE’s stock grew similarly to EDIT’s over the last 12 months.

GYRE's SMR Rating (95) in the null industry is in the same range as EDIT (99) in the Biotechnology industry. This means that GYRE’s stock grew similarly to EDIT’s over the last 12 months.

GYRE's Price Growth Rating (42) in the null industry is in the same range as EDIT (62) in the Biotechnology industry. This means that GYRE’s stock grew similarly to EDIT’s over the last 12 months.

GYRE's P/E Growth Rating (6) in the null industry is significantly better than the same rating for EDIT (100) in the Biotechnology industry. This means that GYRE’s stock grew significantly faster than EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITGYRE
RSI
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
85%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 10 days ago
83%
Declines
ODDS (%)
Bearish Trend 18 days ago
90%
Bearish Trend 4 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
89%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
COMPARISON
Comparison
Sep 28, 2026
Stock price -- (EDIT: $2.58 vs. GYRE: $7.35)
Brand notoriety: EDIT and GYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 131% vs. GYRE: 106%
Market capitalization -- EDIT: $396.24M vs. GYRE: $779.35M
EDIT [@Biotechnology] is valued at $396.24M. GYRE’s [@Biotechnology] market capitalization is $779.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.37B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green while GYRE’s FA Score has 1 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • GYRE’s FA Score: 1 green, 4 red.
According to our system of comparison, GYRE is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 3 TA indicator(s) are bullish while GYRE’s TA Score has 5 bullish TA indicator(s).

  • EDIT’s TA Score: 3 bullish, 7 bearish.
  • GYRE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, GYRE is a better buy in the short-term than EDIT.

Price Growth

EDIT (@Biotechnology) experienced а -4.44% price change this week, while GYRE (@Biotechnology) price change was -2.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.17%. For the same industry, the average monthly price growth was -13.24%, and the average quarterly price growth was +5.35%.

Reported Earning Dates

EDIT is expected to report earnings on Nov 09, 2026.

GYRE is expected to report earnings on Nov 18, 2026.

Industries' Descriptions

@Biotechnology (-4.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
EDIT
Daily Signal:
Gain/Loss:
GYRE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PLAB30.400.59
+1.98%
Photronics
OBIO5.95N/A
N/A
Orchestra BioMed Holdings
AACOU10.10N/A
N/A
Abony Acquisition Corporation I
IBRX8.44-0.20
-2.31%
ImmunityBio
NNOX0.64-0.02
-3.19%
NANO-X IMAGING Ltd

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with BEAM. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
-6.18%
BEAM - EDIT
66%
Loosely correlated
-1.58%
CRBU - EDIT
65%
Loosely correlated
-0.80%
CRSP - EDIT
63%
Loosely correlated
-2.64%
PRME - EDIT
63%
Loosely correlated
-5.54%
VYGR - EDIT
60%
Loosely correlated
-4.29%
More

GYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GYRE has been loosely correlated with SPRC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GYRE jumps, then SPRC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GYRE
1D Price
Change %
GYRE100%
+0.27%
SPRC - GYRE
38%
Loosely correlated
-3.34%
EDIT - GYRE
35%
Loosely correlated
-6.18%
TRDA - GYRE
35%
Loosely correlated
-0.96%
ABSI - GYRE
35%
Loosely correlated
-5.85%
NKTX - GYRE
35%
Loosely correlated
-3.51%
More